KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Non Operating Income (2016 - 2026)

Pacira BioSciences has reported Non Operating Income over the past 17 years, most recently at -$1.9 million for Q1 2026.

  • For Q1 2026, Non Operating Income fell 128.35% year-over-year to -$1.9 million; the TTM value through Mar 2026 reached -$15.6 million, down 376.94%, while the annual FY2025 figure was -$6.6 million, 1674.8% down from the prior year.
  • Non Operating Income for Q1 2026 was -$1.9 million at Pacira BioSciences, up from -$6.1 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $6.7 million in Q1 2025 and troughed at -$25.3 million in Q4 2023.
  • A 5-year average of -$4.9 million and a median of -$422000.0 in 2023 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: plummeted 31301.23% in 2023 and later surged 4380.0% in 2024.
  • Year by year, Non Operating Income stood at $81000.0 in 2022, then plummeted by 31301.23% to -$25.3 million in 2023, then surged by 61.16% to -$9.8 million in 2024, then soared by 38.14% to -$6.1 million in 2025, then skyrocketed by 68.64% to -$1.9 million in 2026.
  • Business Quant data shows Non Operating Income for PCRX at -$1.9 million in Q1 2026, -$6.1 million in Q4 2025, and $3.2 million in Q3 2025.